Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm
Open Access
- 1 April 2024
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 1385-1398
Abstract
In the past few decades, chemotherapy has been one of the most effective cancer treatment options. Drug resistance is currently one of the greatest obstacles to effective cancer treatment. Even though drug resistance mechanisms have been extensively investigated, they have not been fully elucidated. Recent genome-wide investigations have revealed the existence of a substantial quantity of long non-coding RNAs (lncRNAs) transcribed from the human genome, which actively participate in numerous biological processes, such as transcription, splicing, epigenetics, the cell cycle, cell differentiation, development, pluripotency, immune microenvironment. The abnormal expression of lncRNA is considered a contributing factor to the drug resistance. Furthermore, drug resistance may be influenced by genetic and epigenetic variations, as well as individual differences in patient treatment response, attributable to polymorphisms in metabolic enzyme genes. This review focuses on the mechanism of lncRNAs resistance to target drugs in the study of tumors with high mortality, aiming to establish a theoretical foundation for targeted therapy.Keywords
This publication has 99 references indexed in Scilit:
- CTBP1 and CTBP2 mutations underpinning neurological disorders: a systematic reviewneurogenetics, 2022
- Noncoding RNAs in oral cancerWIREs RNA, 2022
- Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathwaysEnvironmental Toxicology, 2021
- A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast CancerThe Oncologist, 2020
- Highly upregulated in liver cancer (HULC): An update on its role in carcinogenesisJournal of Cellular Physiology, 2020
- Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death‐ligand 1 by sponging microRNA‐195‐5pJournal of Cellular Physiology, 2019
- Long noncoding RNAs biomarker‐based cancer assessmentJournal of Cellular Physiology, 2019
- MEG3: an Oncogenic Long Non-coding RNA in Different CancersPathology and Oncology Research, 2019
- Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistanceInternational Journal of Cancer, 2019
- Retracted : Inhibitory role of large intergenic noncoding RNA‐ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathwayJournal of Cellular Physiology, 2018